CN113717909A - 一种达托霉素高产菌株及其应用 - Google Patents
一种达托霉素高产菌株及其应用 Download PDFInfo
- Publication number
- CN113717909A CN113717909A CN202010456478.0A CN202010456478A CN113717909A CN 113717909 A CN113717909 A CN 113717909A CN 202010456478 A CN202010456478 A CN 202010456478A CN 113717909 A CN113717909 A CN 113717909A
- Authority
- CN
- China
- Prior art keywords
- daptomycin
- strain
- recombinant
- recombinant strain
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title claims abstract description 43
- 108010013198 Daptomycin Proteins 0.000 title claims abstract description 42
- 229960005484 daptomycin Drugs 0.000 title claims abstract description 41
- 241000958215 Streptomyces filamentosus Species 0.000 claims abstract description 40
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims abstract description 38
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000004321 preservation Methods 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims description 33
- 230000004151 fermentation Effects 0.000 claims description 33
- 239000013612 plasmid Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 108700005075 Regulator Genes Proteins 0.000 claims description 5
- 101150006779 crp gene Proteins 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 241000187747 Streptomyces Species 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims 2
- 241000223600 Alternaria Species 0.000 claims 1
- 238000012262 fermentative production Methods 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 11
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 201000004569 Blindness Diseases 0.000 abstract description 2
- 241001655322 Streptomycetales Species 0.000 abstract description 2
- 238000009395 breeding Methods 0.000 abstract description 2
- 230000001488 breeding effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002243 precursor Substances 0.000 description 13
- 239000002609 medium Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 10
- 238000010276 construction Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000012137 tryptone Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 229960000210 nalidixic acid Drugs 0.000 description 3
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 2
- 229950006334 apramycin Drugs 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 229910003208 (NH4)6Mo7O24·4H2O Inorganic materials 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 229910004835 Na2B4O7 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 229940010514 ammonium ferrous sulfate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 229940021392 cubicin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及了一种达托霉素高产菌株及其制备方法,重组菌株的分类命名为玫瑰孢链霉菌(Streptomyces roseosporus),保藏号为NO.CGMCC18297。本发明通过使用全局调控因子CRP,解决了传统链霉菌育种的高工作量,高盲目性的问题,得到了利用基因工程培育的达托霉素高产菌株,应用前景广阔;利用该方法对出发菌玫瑰孢链霉菌进行改造,得到的重组菌株能提高玫瑰孢链霉菌对癸酸的耐受度、癸酸利用率,以及提高达托霉素的产量。
Description
技术领域
本发明涉及基因工程技术领域,具体涉及一种达托霉素高产菌株及其制备方法。
背景技术
达托霉素是由玫瑰孢链霉菌(Streptomyces roseosporus)产生的一种新型的环脂肽抗生素,是以钙离子依赖的方式与细胞膜相互作用并发挥杀菌活性。2010 年12月,美国FDA批准了Cubist制药有限公司的达托霉素(daptomycin)注射剂Cubicin以一日1次2min静脉内推注用新给药方案。Cubicin在美最早于2003 年获得批准,用于一日1次30min静脉内输注给药治疗由某些革兰阳性菌、包括耐甲氧西林金黄色葡萄球菌引起的复杂性皮肤和皮肤组织感染,2006年又获得了治疗由对甲氧西林敏感和耐药的金黄色葡萄球菌引起的菌血症、包括右心感染性心内膜炎的新适应证,被视为万古霉素的最佳替代品。我国食品药品监督管理总局分别于2015年和2016年批准了杭州中美华东制药有限公司,浙江海正药业股份有限公司和江苏恒瑞医药股份有限公司生产的注射用达托霉素。多项研究表明达托霉素上市10多年来耐药比例并未显著提高,彰显出达托霉素的独特优势。
达托霉素是一种微生物次级代谢产物,结构复杂,产量非常低,通过基因工程改造是提高达托霉素产量、降低生产成本的重要策略。
癸酸是达托霉素合成中的外源性前体,可改变菌体的次级代谢方向。在达托霉素的生产中,癸酸是必需物质,但过量的癸酸会对玫瑰孢链霉菌产生毒性;相反,若癸酸浓度过低,则会导致前体供应不足而使发酵液中的产品的效价降低。
目前国际上达托霉素发酵单位接近2g/L,而国内整体发酵单位远低于这一水平,针对发酵产量低的现状,国内已经有部分相关研究来提高其产量,但在基因水平上进行定向改造来提高达托霉素的产量报道不多。
发明内容
本发明的目的在于提供一种提高癸酸利用率及耐受度的达托霉素菌株及其构建方法,以解决现有技术中的玫瑰孢链霉菌对前体耐受度低以及达托霉素产量低的技术问题。本发明的菌株的保藏号为CGMCC No.18297。
本发明的目的还在于提供含调控基因的重组质粒的构建方法。
本发明的第三个目在于提供该质粒在达托霉素产生菌遗传改造上的应用。
作为一种具体的实施方式,所述重组菌株的分类命名为玫瑰孢链霉菌(Streptomyces roseosporus),所述重组菌株的保藏号为CGMCC No.18297。
本发明所述重组菌株的保藏信息如下:
保藏时间:2019年7月26日;
保藏单位名称:中国微生物菌种保藏管理委员会普通微生物中心;
保藏编号:CGMCC No.18297;
保藏单位地址:北京市朝阳区北辰西路1号院3号;
分类命名:玫瑰孢链霉菌(Streptomyces roseosporus)。
作为一种具体的实施方式,所述重组菌株为癸酸耐受菌株。
作为一种具体的实施方式,所述重组菌株的癸酸耐受度为出发菌株的两倍。
作为一种具体的实施方式,所述的重组菌株在发酵生产达托霉素中的应用。
作为一种具体的实施方式,所述的重组菌株在提高玫瑰孢链霉菌对癸酸的耐受、提高癸酸利用率及提高达托霉素发酵产量中的应用。
本发明提供的提高达托霉素产量的步骤如下:
(1)通过NCBI数据库得到CRP在玫瑰孢链霉菌中的同源序列,从玫瑰孢链霉菌的基因组中获得CRP的亚克隆片段,将该片段克隆到载体上,得到含有 CRP基因片段的重组质粒。
(2)通过链霉菌结合转移的方法重组质粒导入到玫瑰孢链霉菌 NO.CGMCC4.7231中,通过抗生素筛选得到包含CRP基因的重组菌株。
(3)针对重组菌株进行发酵验证,得到高产菌株。
作为一种具体的实施方式,步骤(1)中的亚克隆片段的核苷酸序列如SEQ ID NO.1所示。
作为一种具体的实施方式,步骤(1)中的载体含有erme启动子。
作为一种具体的实施方式,步骤(1)中的重组质粒为pSET152CRP。
本发明的优点是通过使用全局调控因子CRP,解决了传统链霉菌育种的高工作量,高盲目性的问题,得到了利用基因工程培育的达托霉素高产菌株,应用前景广阔;利用该方法对出发菌玫瑰孢链霉菌进行改造,得到的重组菌株能提高玫瑰孢链霉菌对癸酸的耐受度和利用率,以及提高达托霉素的产量。
附图说明
图1为在培养基中不同前体浓度下,本发明中高抗生素产量玫瑰孢链霉菌与现有玫瑰孢链霉菌发酵产量归一化处理后的对比图;
图2为pSET152CRP的物理图谱;
图3为intΦC31整合方式;
图4为本发明中的构建菌与出发菌在发酵过程中,每日补入正常生产过程中癸酸的量和每日补入两倍正常量的癸酸的两种补料工艺下,每日达托霉素效价归一化处理后的对比图;
图5为本发明中的构建菌与出发菌在发酵过程中,每日补入正常生产过程中癸酸的量和每日补入两倍正常量的癸酸的两种补料工艺下,每日癸酸利用率 (效价/癸酸累计加入量)的对比图。
具体实施方式
下面通过实施例对本发明进行详细说明。
在本发明中,若非特指,所有的设备和原料均可从市场上购得或是本行业常用的,下述实施例中的方法,如无特别说明,均为本领域常规方法。
实施例1:包含CRP基因的重组质粒的pSET152CRP的构建:
通过天蓝色链霉菌中报道的同源基因CRP的核苷酸序列,与NCBI(网站:www.ncbi.nlm.nih.gov)的玫瑰孢链霉菌的基因组序列进行Blast,获得玫瑰孢链霉菌中的目的基因CRP,其大小为672bp。
用primer 5.0设计引物如下:
CRPS:ATTTCTAGAAATACCTGACCGAGCACG;
CRPA:ATTGGATCCATCGCACTGTTTTACCGT。
提取玫瑰孢链霉菌的总DNA,扩增CRP基因,得到目的基因片段。
使用SanPerp柱式质粒DNA小量抽提试剂盒,参照试剂盒说明书方法提取 pSET152质粒。将所得到的质粒DNA溶液置于-20℃保存或用于后续试验。
使用限制性内切酶处理pSET152质粒,酶切后进行DNA琼脂糖凝胶电泳,使用SanPerp柱式DNA胶回收试剂盒,根据说明书操作,回收大小为858bp的片段将所得的DNA溶液置于-20℃保存或用于后续实验。
将扩增后的CRP基因与酶切回收后的pSET152质粒片段进行连接,酶切连接反应体系:载体0.03pmol,片段0.03-0.3pmol,T4 DNA连接酶1200U,缓冲液5ul,剩余体积用蒸馏水补足,16℃连接16h,得到连接产物。
取大肠杆菌感受态细胞200ul,加入上述连接产物,轻轻旋转以混匀内容物,在冰中放置30min。将管放入预加温至42℃的循环水浴中放置90s。快速将管转移到水浴中,使细胞冷却1-2min。每管加入37℃预热的LB培养基800ul,然后转移至37℃水浴45min。将适当体积已转化的感受态细胞转移到含相应抗性的 LB培养基上。37℃倒置培养12-16h后出现菌落。挑取菌落进行酶切验证,取验证成功菌落进行保存及测序验证。
重组质粒pSET152CRP大小为7033bp,带有安普拉抗性基因,可在大肠杆菌和玫瑰孢链霉菌中筛选,intΦC31为整合酶基因,attP为整合位点,p*erme 为红霉素启动子。
LB培养基配方:胰蛋白胨10g,酵母提取物10g,NaCl 10g,加去离子水至 1000ml,PH7.0。在121℃下灭菌30min,用于培养大肠杆菌。固体培养基加入 2%的琼脂粉。
实施例2:将重组质粒通过属间接合转移至玫瑰孢链霉菌
将包含重组质粒PSET152CRP的大肠杆菌ET12567与玫瑰孢链霉菌NO.CGMCC4.7231进行接合转移,用安普拉霉素和萘啶酮酸筛选得到含有 PSET152CRP质粒的接合子,同时用导入空载体PSET152空质粒的载体做对照。
大肠杆菌和玫瑰孢链霉菌NO.CGMCC4.7231属间接合转移的方法:
接种ET12567(PUZ8002/PSET152)和ET12567(PUZ8002/PSET152CRP) 至LB(含卡那霉素/氯霉素/氨苄霉素)培养基,在37℃220rpm的摇床中过夜培养。按1:100的比例分别转接ET12567(PUZ8002/PSET152)和ET12567 (PUZ8002/PSET152CRP)至新鲜的LB培养基(含卡那霉素/氯霉素/氨苄霉素), 37℃,220rpm的摇床中培养至OD600达到0.3~0.4。用相同体积的LB培养基重悬细胞2次,最后重悬于0.1倍体积的LB培养基中。在洗细胞的同时,每次接合转移所需的10-8个孢子悬浮于500ul 2×YT培养基中,50℃热激10min,冷却至室温。各取500ul大肠杆菌液和玫瑰孢链霉菌孢子液充分混匀,离心去倒去大部分的上清,用剩余的液体重悬。将混合好的菌液涂布于含10mM MgCl2的MS 固体培养基,在29℃下培养16-20h。取1ml含0.5mg萘啶酮酸和1mg安普拉霉素的无菌水,在接合转移的平板上均匀覆盖。继续置于29℃培养箱中培养2-3 天,即可观察到接合子。用划线的方法得到含PSET152CRP的玫瑰孢链霉菌单菌落,将单菌落接种至含75ug萘啶酮酸和250ug阿普拉霉素的5mlTSB液体试管中进行传代,验证接合子的基因型。
2×YT培养基配方:
胰蛋白胨16g,酵母提取物10g,NaCl 5g,加入去离子水至1000ml,用5N NaOH调PH至7.0,121℃高压蒸汽灭菌20min。
MS培养基配方:
甘露醇20g,黄豆饼粉20g,琼脂20g,加去离子水至1000ml,PH7.2-7.3, 115℃、15min灭菌两次,使用时加入1M MgCl2至终浓度为10mM/L。(1M MgCl2:MgCl2.7H2O)
实施例3:重组菌发酵工艺
将构建完的玫瑰孢链霉菌菌株在R5斜面培养基30℃培养5d后,将其转移至含50mlYEME液体培养基的摇瓶中,30℃振荡(220rpm/min)培养25h,发酵时采用一次性补入料癸酸作为发酵前体,培养至发酵结束,选取最高产的菌株。由说明书附图1所示与现有的玫瑰孢链霉菌(出发菌)相比,本发明中制得的高抗生素产量玫瑰孢链霉菌具有更高的发酵产量,也就是具有更好的达托霉素产量,发酵产量提高200%以上。
TSB液体培养基配方:
胰酪蛋白胨17g,大豆蛋白胨3g,D-葡萄糖2.5g,氯化钠5g,磷酸氢二钾 2.5g,加入去离子水至1000ml,121℃灭菌30min。
R5培养基配方:
蔗糖103.0g,K2SO4 0.25g,MgCl2·6H20 10.12g,葡萄糖10.0g,水解酪蛋白 0.1g,微量元素溶液2.0g,酵母膏5.0g,TES缓冲液57.3ml,KH2PO4(0.5%)10ml, CaCl2·H2O(5M)4ml,L-脯氨酸(20%)150ml,NaOH(1N)7ml,琼脂20.0g,加去离子水至1000ml,PH 7.2。在115℃灭菌30min。
微量元素溶液(每升):ZnCl2 40mg,FeCl2·6H2O 200mg,CuCl2·2H2O 10mg,MnCl2·2H2O 10mg,Na2B4O7·10H2O 10mg,(NH4)6Mo7O24·4H2O 10mg
YEME培养基配方:
酵母提取物1.5g,胰蛋白胨5g,麦芽提取物3g,葡萄糖10g,蔗糖250g,加入去离子水至1000ml,115℃蒸汽灭菌15min。
实施例4:HPLC测定达托霉素发酵单位:
色谱条件:色谱柱:Phenomenex IB-SIL C8 4.6×250mm 5um,流速:1.0ml/min,检测波长:223nm,进样量:25ul,柱温:25℃,梯度洗脱流动相A:称取3.4g 磷酸二氢铵用1000ml蒸馏水溶解,用磷酸调PH至3.1,流动相B:乙腈。
实施例5:构建菌株对前体浓度的耐受测试
采用实施例3的发酵工艺,在摇瓶中对比出发菌株与构建菌株 NO.CGMCC4.7231对于发酵前体在培养基中浓度的耐受范围。实验结果如说明书附图1所示,构建菌在摇瓶中前体浓度3%~5%时达托霉素的产量最高,超过 5%以后产量有明显的下降;但出发菌产量最高的前体浓度在2%~3%,在3%以后产量就有明显的下降。说明CRP基因可以提高玫瑰孢链霉菌对于培养基中前体的耐受度,在工业生产时可以提高发酵罐中癸酸的加入量,获得单位体积更高的产量。
实施例6:出发菌与构建菌不同的中试发酵工艺对比
按照达托霉素的中试发酵工艺,将构建完的玫瑰孢链霉菌菌株在种子罐中培养22-26小时后,将其转移至发酵罐中,30℃左右培养25h,发酵时连续补料癸酸作为发酵前体,根据构建菌对前体的耐受度,构建均在罐上补入的癸酸量是出发菌正常工艺的两倍。作为对比,出发菌尝试与构建菌使用相同的补料工艺(即癸酸补入量是原始工艺的两倍)。培养至发酵结束,HPLC测定发酵单位,对比。
种子罐配方:马铃薯淀粉6%,葡萄糖1.5%,甘蔗糖蜜0.72%,硫酸亚铁铵0.08%。泡敌0.05%。
发酵罐配方:马铃薯淀粉7.2%,葡萄糖1%,甘蔗糖蜜0.72%,酵母粉 1.2%,硫酸亚铁铵0.086%,泡敌0.05%。
实验结果如说明书附图5所示,在罐上发酵第7天和第8天时,构建菌的效价为出发菌原始工艺的2.5~3倍,是出发菌相同工艺(即癸酸补入量是原始工艺的两倍)的2倍以上。结果显示,在发酵过程中,构建菌的癸酸利用率(以效价/癸酸累计补入量计算)是出发菌原始工艺的2倍以上,同时也比出发菌相同工艺(即癸酸补入量是原始工艺的两倍)明显提高。以上两幅图说明了,首先,构建菌明显提高了罐上达托霉素的表达量,增加了单次发酵的产量;其次,构建菌明显提高了对于癸酸的利用率,使得加入相同量的癸酸后产生更多的达托霉素。
应当理解的是,对于本领域普通技术人员来说,可以根据上述说明加以改进或变换,而所有这些改进和变换都应属于本发明所附权利要求的保护范围。
SEQUENCELISTING
<110>杭州中美华东制药有限公司浙江工业大学
<120>一种达托霉素高产菌株及其应用
<130>1
<160>1
<170>PatentInversion3.5
<210>1
<211>672
<212>DNA
<213>玫瑰孢链霉菌(Streptomycesroseosporus)
<400>1
gcgcgagcgcttcgccagccgctcgacgtccagcaggatgaccgcccgggcctccagccg 60
cagccagccgcggcccgcgaagtccgcgagggccttgttgaccgtctcgcgggaagcgcc 120
gaccagctgggccagctcctcctgggtgaggtcgtgcacgacgtggatgccttcctcgga 180
ctggacgccgaagcggcgcgacaggtccaggagggcgcgggcgacacggcccggcacgtc 240
ggagaagaccaggtcggacatctggtcgttggtcttgcgcagccgtcgggcgaccgcgcg 300
cagcagcgcggtggccacctcgggccgggcgttcagccagggctgcaggtcgccgtggcc 360
gaggccgaggagcttgacctcggtcagtgcggaggcggtcgccgtacgcgggcccgggtc 420
gaagagcgacagctccccgatcagctcgccggggccgagcacggccagcatgttctcgcg 480
cccgtcgggcgaggtgcggtggagcttcaccttgccctcggtgaccacgtacaggcggtc 540
accctggtcgccctcgtggaacagcgcgtctccgcgcgcgagggtcacctcactcatcga 600
ggcgcggagctccgcggcctgctcgtcatcgagcgccgcgaaaagcggggcgcgccgcag 660
aacgtcgtccac 672
Claims (8)
1.一种高产达托霉素的重组菌株,其特征在于,所述重组菌株的分类命名为玫瑰孢链霉菌(Streptomyces roseosporus),所述重组菌株的保藏号为NO.CGMCC18297。
2.根据权利要求1所述的高产达托霉素的重组菌株,其特征在于,所述重组菌株为癸酸耐受菌株。
3.根据权利要求3所述的高产达托霉素的重组菌株,其特征在于,所述重组菌株的癸酸耐受度为出发菌株的两倍。
4.权利要求1-3任一项所述的高产达托霉素的重组菌株构建方法,其特征在于,包括以下步骤:
1)获取SEQ ID NO.1所示的编码CRP蛋白的调控基因;
2)将所述调控基因与表达载体连接,构建重组质粒;
3)将所述重组质粒导入玫瑰孢链霉菌株,得到重组菌株。
5.根据权利要求4所述的高产达托霉素的重组菌株构建方法,其特征在于,所述步骤1)优选为从玫瑰孢链霉菌中获取SEQ ID NO.1所示的编码CRP蛋白的调控基因;
所述步骤2)优选为将CRP蛋白的调控基因克隆到含强启动子的表达载体PSET152上,得到含CRP基因的重组质粒,所述重组质粒的核苷酸序列如SEQ ID NO.2所示;
所述步骤3)优选为通过接合转移的方法,将步骤(2)得到的重组质粒转移到玫瑰孢链霉菌中,获得重组菌株。
6.根据权利要求4所述的高产达托霉素的重组菌株,其特征在于,通过将步骤3)得到的重组菌株进行抗生素筛选,发酵培养及达托霉素效价测定,获得达托霉素高产的链霉菌菌株。
7.权利要求1-3任一项所述的重组菌株在发酵生产达托霉素中的应用。
8.权利要求1-3任一项所述的重组菌株在提高玫瑰孢链霉菌对癸酸的耐受度、利用率及提高达托霉素发酵产量中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010456478.0A CN113717909A (zh) | 2020-05-26 | 2020-05-26 | 一种达托霉素高产菌株及其应用 |
PCT/CN2021/095417 WO2021238832A1 (zh) | 2020-05-26 | 2021-05-24 | 一种达托霉素高产菌株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010456478.0A CN113717909A (zh) | 2020-05-26 | 2020-05-26 | 一种达托霉素高产菌株及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113717909A true CN113717909A (zh) | 2021-11-30 |
Family
ID=78672041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010456478.0A Pending CN113717909A (zh) | 2020-05-26 | 2020-05-26 | 一种达托霉素高产菌株及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113717909A (zh) |
WO (1) | WO2021238832A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116731134B (zh) * | 2023-04-28 | 2024-05-31 | 中国农业科学院植物保护研究所 | 一种糖转运蛋白tp6568及其在改造高产链霉菌中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003014297A2 (en) * | 2001-08-06 | 2003-02-20 | Cubist Pharmaceuticals, Inc. | Compositions and methods relating to the daptomycin biosynthetic gene cluster |
CN101302531A (zh) * | 2008-06-20 | 2008-11-12 | 南京师范大学 | 一种在大肠杆菌-链霉菌-假单胞菌之间穿梭表达的bac载体及其构建方法 |
US20110143394A1 (en) * | 2006-02-14 | 2011-06-16 | Universiteit Leiden | Methods and Means for Metabolic Engineering and Improved Product Formation by Micro-Organisms |
CN102146414A (zh) * | 2010-07-26 | 2011-08-10 | 天津大学 | 玫瑰孢链霉菌基因工程菌的构建方法及其应用 |
CN102586147A (zh) * | 2012-02-17 | 2012-07-18 | 厦门大学 | 一种可高产达托霉素的玫瑰孢链霉菌的筛选方法 |
US20180237847A1 (en) * | 2015-08-20 | 2018-08-23 | Genomatica, Inc. | Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them |
WO2019195655A1 (en) * | 2018-04-06 | 2019-10-10 | University Of Florida Research Foundation, Incorporated | Engineered streptomyces albus strains |
CN113717259A (zh) * | 2020-05-26 | 2021-11-30 | 浙江工业大学 | 一种玫瑰孢链霉菌中提高癸酸利用率及耐受度的调控基因及应用 |
-
2020
- 2020-05-26 CN CN202010456478.0A patent/CN113717909A/zh active Pending
-
2021
- 2021-05-24 WO PCT/CN2021/095417 patent/WO2021238832A1/zh active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003014297A2 (en) * | 2001-08-06 | 2003-02-20 | Cubist Pharmaceuticals, Inc. | Compositions and methods relating to the daptomycin biosynthetic gene cluster |
US20110143394A1 (en) * | 2006-02-14 | 2011-06-16 | Universiteit Leiden | Methods and Means for Metabolic Engineering and Improved Product Formation by Micro-Organisms |
CN101302531A (zh) * | 2008-06-20 | 2008-11-12 | 南京师范大学 | 一种在大肠杆菌-链霉菌-假单胞菌之间穿梭表达的bac载体及其构建方法 |
CN102146414A (zh) * | 2010-07-26 | 2011-08-10 | 天津大学 | 玫瑰孢链霉菌基因工程菌的构建方法及其应用 |
CN102586147A (zh) * | 2012-02-17 | 2012-07-18 | 厦门大学 | 一种可高产达托霉素的玫瑰孢链霉菌的筛选方法 |
US20180237847A1 (en) * | 2015-08-20 | 2018-08-23 | Genomatica, Inc. | Compositions and multiplexed systems for coupled cell-free transcription-translation and protein synthesis and methods for using them |
WO2019195655A1 (en) * | 2018-04-06 | 2019-10-10 | University Of Florida Research Foundation, Incorporated | Engineered streptomyces albus strains |
CN113717259A (zh) * | 2020-05-26 | 2021-11-30 | 浙江工业大学 | 一种玫瑰孢链霉菌中提高癸酸利用率及耐受度的调控基因及应用 |
Non-Patent Citations (4)
Title |
---|
CHAN GAO等: "Crp Is a Global Regulator of Antibiotic Production in Streptomyces", 《MBIO》, vol. 3, no. 6, 11 December 2012 (2012-12-11), pages 1 - 12, XP055871565, DOI: 10.1128/mBio.00407-12 * |
CHUN-YAN LIN等: "Regulatory Patterns of Crp on Monensin Biosynthesis in Streptomyces cinnamonensis", 《MICROORGANISMS》, vol. 8, no. 2, 17 February 2020 (2020-02-17), pages 1 - 14, XP055872412, DOI: 10.3390/microorganisms8020271 * |
XU-MING MAO等: "Transcriptional Regulation of the Daptomycin Gene Cluster in Streptomyces roseosporus by an Autoregulator, AtrA", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 290, no. 12, 20 March 2015 (2015-03-20), pages 7992, XP055872409, DOI: 10.1074/jbc.M114.608273 * |
彭希希 等: "《新型环脂肽抗生素达托霉素研究进展》", 《药学学报》, vol. 53, no. 6, 31 December 2018 (2018-12-31), pages 839 - 844 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021238832A1 (zh) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100436594C (zh) | 发酵制造s-腺苷甲硫氨酸的方法 | |
CN107916283B (zh) | 一种烟酰胺的生产工艺 | |
CN116751731B (zh) | 一种大规模质粒生产的发酵工艺 | |
CN104762247A (zh) | 提高生产子囊霉素产量的基因工程菌株及构建方法 | |
WO2021238841A1 (zh) | 一种玫瑰孢链霉菌中提高癸酸利用率及耐受度的调控基因及应用 | |
CN108441459A (zh) | 一种高产两性霉素b的重组结节链霉菌及其应用 | |
CN109486834B (zh) | 高产乳酸链球菌素的重组乳酸乳球菌及构建方法 | |
CN113717909A (zh) | 一种达托霉素高产菌株及其应用 | |
CN113801834B (zh) | 一种基因工程高产丰加霉素的淀粉酶产色链霉菌及其构建方法和应用 | |
US20210324391A1 (en) | Recombinant microorganism, preparation method therefor and application thereof in producing coenzyme q10 | |
CN111019965A (zh) | 新霉素生物合成基因簇遗传改造的工程菌及其应用 | |
CN109136253A (zh) | 一种通过糖多孢红霉菌sace_5754基因途径提高红霉素产量的方法 | |
CN110577921B (zh) | 产两性霉素b的重组结节链霉菌及其应用 | |
CN109628366B (zh) | 一种提高乳酸菌抗酸胁迫能力的方法 | |
CN109852571B (zh) | 一种抗酸能力强的乳酸菌工程菌及构建方法和应用 | |
CN113462628A (zh) | 一株产血红素的基因工程菌及其构建方法和应用 | |
CN112195117A (zh) | 一株大肠杆菌及其在生物催化生产低副产物烟酰胺中的应用 | |
CN114806992B (zh) | 一种rsh过表达基因工程淀粉酶产色链霉菌及提高丰加霉素发酵产量的方法 | |
CN118389395B (zh) | 一种产缬氨酸的重组菌及其构建方法与应用 | |
CN116286575B (zh) | 一种利用枯草芽孢杆菌高效表达生淀粉α-淀粉酶的方法 | |
CN113755517B (zh) | 一种slcg_5407基因改造型林可链霉菌的构建方法与应用 | |
CN117363552B (zh) | 生产纳他霉素的褐黄孢链霉菌基因工程菌株及其构建方法 | |
CN112592878B (zh) | 增强正调控蛋白基因表达以提高阿卡波糖发酵水平的方法 | |
CN116515648A (zh) | 一种高产ε-聚赖氨酸及其盐酸盐的基因工程菌株、构建方法及其应用 | |
CN116042416B (zh) | 高产ε-聚赖氨酸的多基因过表达链霉菌工程菌株及方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |